⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 15, 2025

Supplementary Figure S1 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition

Qi Ye Bohan Ma Lei Li Zixi Wang Mingming Lu Jialu Kang Yuzeshi Lei Shan Xu Ke Wang Yanlin Jian Yizeng Fan Bin Wang Jing Liu Yang Gao Jian Ma Lei Li

View Full Paper

Ask AI

Bookmark

Share

Key Points

The BRCA2-targeting PROTAC drug enhances the efficacy of PARP inhibition against cancer cells.
Characterization shows significant features in the design and mechanism of the PROTAC drug.
This approach may offer therapeutic advantages for metastatic castration-resistant prostate cancer treatment.
Further studies are needed to validate the drug's effectiveness in clinical settings.

Implication

This analysis reveals the design of a PROTAC drug targeting BRCA2 in prostate cancer, suggesting improved inhibition efficacy.

Abstract

Supplementary Fig. S1. Design and characterization of the BRCA2-targeting peptide PROTAC drug. Related to Fig. 1.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ye et al. (2025) studied this question.

synapsesocial.com/papers/68d46ccf31b076d99fa68fb5 https://doi.org/10.1158/0008-5472.30125758

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S2 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025
2Supplementary Figure S3 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025
3Supplementary Figure S6 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025
4Supplementary Figure S5 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025
5Supplementary Figure S7 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025